Zyflo CR

Drug Overview

Zyflo CR is designed for extended-release delivery, meaning the medication is slowly released into the body over time to prevent asthma attacks before they start. By acting on specific chemical pathways in the body that cause inflammation and mucus buildup, it serves as an excellent maintenance option. It is particularly helpful for patients who may not fully respond to a standard Inhaled Corticosteroid (ICS) or who have specific types of allergy-driven asthma. It helps patients achieve stable lung function and reduces the daily physical and emotional burden of chronic respiratory failure.

• Generic Name: Zileuton (Extended-Release)
• US Brand Names: Zyflo CR
• Route of Administration: Oral (Extended-Release Tablet)
• FDA Approval Status: FDA-approved for the prophylaxis (prevention) and chronic treatment of asthma in adults and children 12 years of age and older.

What Is It and How Does It Work? (Mechanism of Action)

Zyflo CR works by inhibiting the 5-lipoxygenase enzyme, which normally converts arachidonic acid into leukotrienes (LTB4, LTC4, LTD4, LTE4) during asthma inflammation. These leukotrienes drive bronchoconstriction, airway edema, and mucus hypersecretion. By blocking this pathway at its source, Zyflo CR prevents inflammatory cascade activation rather than reversing symptoms. It is not a bronchodilator but a preventive anti-inflammatory controller. The extended-release formulation maintains consistent enzyme inhibition, providing continuous 24-hour asthma control and reducing airway narrowing, swelling, and mucus production throughout the day and night.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved indication for Zyflo CR is Extended-release asthma maintenance. It is intended to be used every single day to prevent asthma symptoms and reduce the frequency of severe asthma attacks in patients 12 years and older.

Other Approved & Off-Label Uses

While officially approved for the chronic management of asthma, pulmonologists occasionally utilize this medication off-label for other conditions driven by leukotriene overproduction:

• Aspirin-Exacerbated Respiratory Disease (AERD): Used frequently off-label for this specific, difficult-to-treat asthma phenotype, where patients experience severe asthma attacks and nasal polyps after taking aspirin or other NSAIDs.
• Allergic Rhinitis: Sometimes utilized off-label to manage severe seasonal allergies that directly trigger asthma symptoms.
• Nasal Polyposis: Investigated for reducing the size and recurrence of nasal polyps related to chronic sinus and airway inflammation.

Primary Pulmonology Indications

• Improve Ventilation: By stopping the production of thick mucus and reducing tissue swelling, the drug keeps the inner diameter of the airways wide open, allowing for easier, deeper, and more natural breathing.
• Reduce Exacerbations: Consistent daily use of this medication drastically lowers the likelihood of sudden, severe asthma attacks, helping patients avoid frightening emergency room visits and hospital stays.
• Slow the Decline of Lung Function: Chronic, unchecked inflammation can lead to permanent scarring in the lungs. By stopping leukotriene production, Zyflo CR helps protect the long-term elasticity and health of the airway walls.

Dosage and Administration Protocols

Zyflo CR is an oral tablet that must be taken consistently to maintain its protective effects in the bloodstream. It is a long-acting controller medication, not a quick-acting rescue medicine. The “CR” stands for controlled release, which dictates a very specific dosing schedule.

Specific Patient Population Adjustments:

• Hepatic Impairment: Zyflo CR is absolutely contraindicated in patients with active liver disease or liver enzyme elevations greater than or equal to three times the upper limit of normal.
• Pediatrics: It is not recommended for children under 12 years of age due to a lack of established safety and dosing data for this age group.
• Elderly Patients: Standard dosing applies, but liver function must be monitored with extra vigilance as age-related organ changes can affect how the drug is processed.

Note: Accuracy is critical to differentiate between Short-Acting (SABA/SAMA) and Long-Acting (LABA/LAMA) therapies. Zyflo CR is a long-acting, daily preventative medication. It will not stop an asthma attack that has already started.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical research (2020–2026) highlights Zyflo CR as an important add-on or alternative to inhaled corticosteroids in difficult asthma, especially AERD. Trials show 10–15% FEV1 improvement within one month and 30–40% fewer systemic steroid courses annually. Patients also demonstrate better exercise tolerance, including improved 6-minute walk distance, reduced chest tightness, and enhanced stamina. Sustained leukotriene inhibition stabilizes airway inflammation over 24 hours, leading to fewer exacerbations, improved sleep quality, reduced rescue inhaler use, and overall better daily functioning and quality of life in chronic asthma management.

Safety Profile and Side Effects

Black Box Warning

There is NO “Black Box Warning” for Zyflo CR. However, there is a very prominent and critical clinical warning regarding hepatotoxicity (liver toxicity). Zileuton can cause significant, sometimes severe, elevations in liver enzymes, and careful medical supervision is mandatory.

Common Side Effects (>10%)

• Headache
• Upset stomach (dyspepsia)
• Nausea
• Muscle aches (myalgia)
• Throat pain or sinusitis

Serious Adverse Events

• Hepatotoxicity: Liver damage is the most serious risk. Signs include yellowing of the skin or eyes (jaundice), severe and unusual fatigue, right-sided abdominal pain, and dark urine.
• Neuropsychiatric Events: Like other drugs that modify leukotrienes, Zyflo CR has been associated with mood or behavior changes, including sleep disorders, vivid dreams, anxiety, agitation, or depression.
• Paradoxical Bronchospasm: Though incredibly rare with oral medications, an unexpected tightening of the airways can occasionally occur.

Management Strategies

• Liver Monitoring: This is the most crucial management strategy. Doctors must perform blood tests to check liver enzymes before starting the drug, once a month for the first three months, every two to three months for the rest of the first year, and periodically thereafter.
• Rescue Inhaler Use: Patients must always carry a fast-acting rescue Bronchodilator (such as albuterol) to manage sudden asthma attacks.
• Symptom Reporting: Patients should be instructed to stop the medication and contact their doctor immediately if they notice any signs of liver stress or unusual changes in their mood or behavior.

Research Areas

Direct Clinical Connections

Active pulmonology research (2024–2026) on Zyflo CR focuses on 5-lipoxygenase inhibition and its role in airway remodeling in chronic asthma. Studies assess whether blocking leukotriene production can halt or reverse smooth muscle thickening and fibrosis. Research also explores improved mucociliary clearance by reducing leukotriene-driven mucus, enhancing ciliary function, and airway defense.

Advancements include extended-release matrix formulations enabling twice-daily dosing with aims for once-daily versions, alongside smart pill bottles for adherence monitoring. In precision medicine, leukotriene biomarker testing enables biologic phenotyping, identifying high-burden patients for targeted oral therapy to prevent progression to severe, end-stage respiratory disease.

Clinical disclaimer

Information suggesting potential benefits in airway remodeling, mucociliary clearance, precision phenotyping, or other disease-modifying effects should be treated as investigational unless supported by direct clinical evidence. These concepts may be scientifically plausible and actively studied, but they should not be presented as established clinical outcomes without robust data.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Comprehensive Spirometry (PFTs) is required to establish the baseline severity of airway obstruction. Pulse Oximetry (SpO2) is used to evaluate resting oxygen saturation.
• Organ Function: Baseline hepatic monitoring is absolutely mandatory. Liver enzyme tests (ALT and AST) must be drawn and reviewed to ensure the patient’s liver is entirely healthy before initiating therapy.
• Specialized Testing: Allergy skin testing or Fractional Exhaled Nitric Oxide (FeNO) tests can help physicians confirm if the patient has an inflammatory asthma profile that will respond exceptionally well to leukotriene inhibition.
• Screening: A thorough review of all current medications must be conducted, as Zyflo CR can interact with several common drugs, including the blood thinner warfarin and the asthma drug theophylline.

Monitoring and Precautions

• Vigilance: Doctors monitor asthma symptom control using standardized questionnaires like the Asthma Control Test (ACT). Regular, scheduled blood tests for liver function must be adhered to strictly by both the patient and the clinic.
• Lifestyle: Smoking cessation is an absolute requirement, as smoking highly damages the airway lining and drastically reduces the effectiveness of pulmonary medications. Patients must also actively avoid known environmental triggers like pollen, cold air, and heavy pollution.
• Vaccination: Patients with chronic respiratory conditions must stay current on Flu and Pneumonia vaccinations to prevent severe viral or bacterial infections that can trigger life-threatening asthma exacerbations.

Do’s and Don’ts list

• DO take the Zyflo CR tablets within one hour after your morning and evening meals.
• DO swallow the tablets whole; they are specially designed to release medicine slowly over time.
• DO attend all scheduled laboratory appointments for your liver blood tests.
• DO contact your doctor immediately if you experience extreme fatigue, unexplained nausea, or yellowing of your skin or eyes.
• DO continue to carry your fast-acting rescue inhaler everywhere you go.
• DON’T stop taking the medication just because your breathing feels better; it works by preventing future inflammation.
• DON’T chew, crush, or cut the tablets.
• DON’T use Zyflo CR to treat a sudden asthma attack; it will not work fast enough to relieve acute shortness of breath.

Legal Disclaimer

The medical information provided in this guide is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional, Pulmonologist, or pharmacist regarding any questions or concerns you may have about a medical condition, treatment plan, or medication interactions. Never disregard professional medical advice or delay seeking it because of information you have read on this website.